Welcome to our dedicated page for Nutriband news (Ticker: NTRB), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.
About Nutriband Inc.
Nutriband Inc. (NASDAQ: NTRB) is a pharmaceutical company headquartered in Oviedo, Florida, specializing in the development and commercialization of innovative transdermal drug delivery systems. The company’s primary focus lies in leveraging its proprietary AVERSA™ abuse-deterrent technology to address critical safety concerns in the pharmaceutical industry, particularly related to opioid medications. By integrating aversive agents into transdermal patches, Nutriband enhances safety by preventing the abuse, misuse, diversion, and accidental exposure of drugs with high abuse potential, such as opioids and stimulants.
Core Business and Technology
Nutriband’s flagship product under development is the AVERSA™ Fentanyl transdermal patch, which aims to become the world’s first abuse-deterrent opioid patch. This innovative technology incorporates aversive agents, such as denatonium benzoate (Bitrex®), to create a bitter taste that deters oral abuse and accidental exposure, particularly in children. The AVERSA™ platform technology is versatile and can be applied to other transdermal formulations, broadening its potential applications in the pharmaceutical market.
The company operates within a robust intellectual property framework, with patents granted in 46 countries, including the United States, Europe, Japan, Korea, Russia, China, Canada, and Australia. This extensive portfolio underscores Nutriband’s commitment to securing its technological innovations on a global scale.
Revenue Streams and Market Reach
Nutriband generates revenue through multiple channels, including the sale of consumer transdermal and coated products, as well as contract manufacturing services provided by its subsidiary, Pocono Pharma. Pocono Pharma specializes in kinesiology tape manufacturing and serves major retail clients, such as Target, Walmart, Walgreens, and CVS. This diversification not only strengthens Nutriband’s financial foundation but also positions it as a trusted partner in the manufacturing of specialized consumer healthcare products.
Industry Context and Competitive Position
Nutriband operates at the intersection of the pharmaceutical and healthcare industries, addressing critical challenges such as the opioid crisis and medication safety. The company’s AVERSA™ technology aligns with growing regulatory and societal demand for safer drug delivery systems. By focusing on transdermal solutions, Nutriband differentiates itself from competitors that primarily rely on traditional oral or injectable drug formulations. Its partnership with Kindeva Drug Delivery, a leading contract development and manufacturing organization, further enhances its capabilities in scaling and commercializing its products.
Intellectual Property and Global Expansion
With patents issued in major global markets, Nutriband has established a strong foundation for international expansion. Recent advancements include the extension of its intellectual property to regions such as Hong Kong and Macao, further solidifying its presence in Asia. These developments position Nutriband as a leader in the abuse-deterrent pharmaceutical space, capable of addressing both regional and global market needs.
Commitment to Innovation and Patient Safety
At its core, Nutriband is driven by a mission to enhance patient safety through innovative technologies. The AVERSA™ platform not only addresses the risks associated with opioid misuse but also ensures that essential medications remain accessible to patients who need them. This dual focus on safety and accessibility underscores Nutriband’s role as a socially responsible player in the pharmaceutical industry.
Conclusion
In summary, Nutriband Inc. is a pioneering company in the field of transdermal drug delivery, leveraging its proprietary AVERSA™ technology to address pressing healthcare challenges. With a diversified revenue model, strong intellectual property portfolio, and strategic partnerships, Nutriband is well-positioned to make a meaningful impact in the pharmaceutical and healthcare industries.
Nutriband (NASDAQ:NTRB), a developer of transdermal pharmaceuticals and technology, will host an exclusive live investor webinar on May 30, 2024, at 4:15 p.m. ET.
Organized by RedChip Companies, the event will feature Chairman Serguei Melnik and CEO Gareth Sheridan, who will provide insights into the company's current operations and future milestones.
Investors can register for the free webinar and submit questions beforehand or during the live session.
Nutriband announced the appointment of Sergei Glinka to its board of directors. Glinka, an experienced business leader, brings a wealth of experience from his roles in major European companies. The Glinka family has invested $4.5 million in Nutriband via a private placement in April 2024, which totaled $8.4 million. Nutriband aims to use these funds to complete the FDA approval process for its AVERSA™ technology. AVERSA™, currently patented in 45 countries, is projected to reach peak annual US sales between $80 million and $200 million. The global opioid market was valued at $22.8 billion in 2022.
RedChip Companies will air interviews with Can-Fite BioPharma (NYSE American:CANF) and Nutriband Inc. (NASDAQ:NTRB) on the RedChip Small Stocks, Big Money™ show on Bloomberg TV. Pnina Fishman, Executive Chairperson and Chief Scientific Officer of Can-Fite BioPharma, discusses the company's advanced clinical stage drug development focusing on oncology and inflammatory diseases. Can-Fite has two drug candidates in advanced stages of development with registration plans agreed with the U.S. FDA and the EMA. Gareth Sheridan, Founder and CEO of Nutriband, talks about their AVERSA™ abuse-deterrent transdermal technology to address the global opioid crisis. Nutriband's lead product, AVERSA™ Fentanyl, is targeting peak annual sales of $80 million to $200 million.
FAQ
What is the current stock price of Nutriband (NTRB)?
What is the market cap of Nutriband (NTRB)?
What is Nutriband Inc.'s primary focus?
What is AVERSA™ technology?
How does Nutriband generate revenue?
What is the significance of Nutriband's intellectual property portfolio?
Who are Nutriband's strategic partners?
What problem does Nutriband aim to solve?
What is Nutriband's flagship product?
What industries does Nutriband operate in?
